Compare · GRDX vs NVO
GRDX vs NVO
Side-by-side comparison of GridAI Technologies Corp. (GRDX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRDX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 24087.5x GRDX ($7.6M).
- Over the past year, GRDX is up 117.0% and NVO is down 34.2% - GRDX leads by 151.3 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 2 for GRDX).
- NVO has more recent analyst coverage (25 ratings vs 0 for GRDX).
- Company
- GridAI Technologies Corp.
- Novo Nordisk A/S
- Price
- $2.31+2.44%
- $41.18+6.93%
- Market cap
- $7.6M
- $183.82B
- 1M return
- +12.99%
- +13.32%
- 1Y return
- +117.04%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 2
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GRDX
- GridAI Technologies Corp. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation
- Amendment: GridAI Technologies Corp. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form NT 10-K filed by GridAI Technologies Corp.
- SEC Form RW filed by GridAI Technologies Corp.
- Powell Max Limited Successfully Repositions for Its Next Phase of Growth
- IBN Announces Latest Episode of The TechMediaWire Podcast featuring Marshall Chapin, CEO of Grid AI Corp.
- GridAI Technologies Corp. Identifies Amp Z as Previously Announced Stealth Hyperscaler AI Data Center Developer
- Amendment: SEC Form SCHEDULE 13G/A filed by GridAI Technologies Corp.
- GridAI Technologies Corp. Appoints Veteran Energy Executive Tim Healy as Executive Chairman of Grid AI Corp.
- GridAI Technologies Corp. Appoints Veteran Energy Executive Tim Healy as Executive Chairman of Grid AI Corp.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S